

SUPPLEMENTARY TABLE 1. SUMMARY CHARACTERISTICS OF ELIGIBLE STUDIES FOR OVERALL AND SUBGROUP STRATIFIED BY THE STUDY CHARACTERISTIC OF ETHNICITY, CANCER TYPES, STUDY DESIGN, SAMPLE SIZE, AND GENOTYPING METHOD

Group	N ^a	Cases/Controls	Case					Control				
			C	T	CC	CT	TT	C	T	CC	CT	TT
Overall	73	15942/22336	20100	11784	6971	6158	2813	27356	17316	9359	8638	4339
Ethnicity												
African	2	255/754	320	190	102	116	37	909	599	285	339	130
Asian	31	5442/7911	4519	6365	1072	2375	1995	6142	9680	1399	3344	3168
European	27	5437/8036	8161	2713	3078	2005	354	12110	3962	4601	2908	527
Mixed	13	4808/5635	7100	2516	2719	1662	427	8195	3075	3074	2047	514
Cancer type												
bladder	2	1231/1447	1673	789	589	495	147	1933	961	676	581	190
breast	4	1278/1512	1722	834	625	472	181	2010	1014	720	570	222
cervical	3	948/947	1284	612	460	364	124	1307	587	497	313	137
colorectal	3	477/544	701	253	260	181	36	835	253	321	193	30
esophageal	2	277/592	338	216	124	90	63	585	599	176	233	183
gallbladder	2	319/773	238	400	55	128	136	550	996	95	360	318
gastric	15	2783/5198	2541	3025	687	1167	929	5130	5266	1539	2052	1607
Asian	10	1968/3053	1323	2613	211	901	856	1923	4183	325	1273	1455
European	3	456/1890	695	217	273	149	34	2823	957	1069	685	136
hepatocellular	4	905/1074	1051	759	335	381	189	1174	974	365	444	265
Laposi sarcoma	1	132/168	187	77	64	59	9	243	93	92	59	17
leukemia	2	47/65	60	34	20	20	7	99	31	35	29	1
lung	4	503/795	536	470	165	206	132	912	678	304	304	187
Asian	3	320/372	263	377	65	133	122	266	478	53	160	159
lymphoma	7	1747/1820	2662	832	1006	650	91	2757	883	1040	677	103
European	5	718/758	1064	372	390	284	44	1128	388	416	296	46
melanoma	5	530/540	808	252	306	196	28	810	270	302	206	32
European	3	290/306	449	131	173	103	14	454	158	171	112	23
multiple myeloma	2	166/549	252	80	96	60	10	830	268	314	202	33
nasopharyngeal	2	287/340	283	291	83	117	87	334	346	94	146	100
oral	1	280/300	214	346	47	120	113	208	392	37	134	129
ovarian	3	361/438	325	397	102	121	138	419	457	151	117	170
prostate	7	2891/3804	4010	1772	1469	1072	350	5090	2518	1796	1498	510
renal	2	156/225	239	73	94	51	11	326	124	122	82	21
testicular	1	504/605	777	231	302	173	29	901	309	342	217	46
mixed	1	120/600	199	41	82	35	3	903	297	341	221	38
Study design												
HCC	42	7476/9273	8652	6300	2805	3042	1629	10322	8224	3289	3744	2240
PCC	29	8027/11765	10772	5282	3906	2960	1161	15073	8457	5320	4433	2012
NCC	2	439/1298	676	202	260	156	23	1961	635	750	461	87
Sample size												
< 500	48	5471/7263	6248	4694	2024	2200	1247	7650	6876	2387	2876	2000
≥ 500	25	10471/15073	13852	7090	4947	3958	1566	19706	10440	6972	5762	2339
Genotyping method												
PCR-RFLP	16	3147/3724	3075	3219	869	1337	941	3377	4071	917	1543	1264
TaqMan	25	8172/11557	11863	4481	4450	2963	759	16081	7033	5871	4339	1347
other	32	4623/7055	5162	4084	1652	1858	1113	7898	6212	2571	2756	1728

^aNumber of studies. HCC, hospital-based case-control; HWE, Hardy-Weinberg equilibrium; NCC, nested case-control study; PCC, population-based case-control; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.